Checkpoint Inhibitors Market 2024 – By Size, Share, Growth And Global Forecast Report 2033

Overview and Scope
Checkpoint inhibitors refer to an immunotherapy strategy that prevents immune checkpoint proteins from forming interactions with other proteins. Because of this, the T cells are able to destroy cancer cells because the “”off”” signal is not sent. One such medication works against the checkpoint protein CTLA-4.

Sizing and Forecast
The checkpoint inhibitors market size has grown rapidly in recent years. It will grow from $32.41 billion in 2023 to $37.88 billion in 2024 at a compound annual growth rate (CAGR) of 16.9%.  The  growth in the historic period can be attributed to rising incidence of cancer,  increasing awareness of checkpoint inhibitors, expanding range of approved checkpoint inhibitors, research and development on checkpoints novel inhibitors, clinical trials and research.

The checkpoint inhibitors market size is expected to see rapidly grown in the next few years. It will grow to $55.64 billion in 2028 at a compound annual growth rate (CAGR) of 10.1%.  The growth in the forecast period can be attributed to expanding indications, biomarker discovery, combination therapies, personalized medicine, expanded indications. Major trends in the forecast period include precision immunotherapy, immune checkpoint combinations, cell therapy integration, biosimilars, immunotherapy combinations, .

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/checkpoint-inhibitor-global-market-report

Segmentation & Regional Insights

The checkpoint inhibitors market covered in this report is segmented –

1) By Drug: PD-1 Inhibitors, PD-L1 Inhibitors, CTLA-4, Chimeric Antigen Receptor T-cell, Other Drugs

2) By Application: Lung Cancer, Renal Cancer, Blood Cancer, Bladder Cancer, Melanoma, Other Applications

3) By End-Users: Hospitals Pharmacies, Retail Pharmacies, Online Pharmacies

North America was the largest region in the checkpoint inhibitors market in 2023. The Middle East is expected to be the fastest growing region in the global checkpoint inhibitors market share during the forecast period. The regions covered in the checkpoint inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=3413&type=smp

Major Driver Impacting Market Growth
The rise in the number of cancer cases across the globe is likely to contribute to the growth of the checkpoint inhibitors market during the forecast period. For instance, in January 2022, according to the American Cancer Society, there will likely be 1.9 million new cancer diagnoses and 609,360 cancer-related deaths in the US, or roughly 1,670 fatalities every day. The four most common types of cancer worldwide are lung, prostate, bowel, and female breast cancer, accounting for 43 percent of all new cancer cases. Checkpoint inhibitors targeting the checkpoints are very helpful as cancer therapies. Therefore, the rise in cancer incidence rates globally is anticipated to boost for checkpoint inhibitors market demand.

Key Industry Players
Major companies operating in the checkpoint inhibitors market include  AstraZeneca plc, Bristol-Myers Squibb Company, Merck & Co. Inc., Roche Holding AG, Pfizer Inc., Incyte Corporation, Novartis AG, NewLink Genetics Corporation, Seattle Genetics Inc., Celldex Therapeutics, GlaxoSmithKline plc, Innate Pharma S.A., Ono Pharmaceutical Co. Ltd., Juno Therapeutics, Kite Pharma, Eli Lilly and Company (ARMO Biosciences.), Fortress Biotech, Argenx SE, MacroGenics, CureTech, Sorrento Therapeutics, Sanofi S.A, F. Hoffmann-La Roche Ltd, AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Bayer AG, Biogen Inc., Boehringer Ingelheim International GmbH, Celgene Corporation, Daiichi Sankyo Company Limited, Eisai Co. Ltd., Gilead Sciences Inc., Kyowa Kirin Co. Ltd., Johnson & Johnson, Regeneron Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, Teva Pharmaceutical Industries Ltd., Vertex Pharmaceuticals Incorporated, Y-mAbs Therapeutics Inc., Zai Lab Limited

The checkpoint inhibitors market report table of contents includes:
1. Executive Summary
2. Checkpoint Inhibitors Market Characteristics
3. Checkpoint Inhibitors Market Trends And Strategies
4. Checkpoint Inhibitors Market – Macro Economic Scenario
5. Global Checkpoint Inhibitors Market Size and Growth
……………………………
31. Global Checkpoint Inhibitors Market Competitive Benchmarking
32. Global Checkpoint Inhibitors Market Competitive Dashboard
33. Key Mergers And Acquisitions In The Checkpoint Inhibitors Market
34. Checkpoint Inhibitors Market Future Outlook and Potential Analysis
35. Appendix

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

Twitter: https://twitter.com/tbrc_info

Facebook: https://www.facebook.com/TheBusinessResearchCompany

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Blog: https://blog.tbrc.info/

Healthcare Blog: https://healthcareresearchreports.com/

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model